Elana Jaffe is with the Center for Bioethics, Department of Social Medicine, School of Medicine, and the Department of Maternal, Child, and Family Health, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Ilona Telefus Goldfarb is with the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Anne Drapkin Lyerly is with the Center for Bioethics, Department of Social Medicine, and the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill.
Am J Public Health. 2021 Mar;111(3):498-503. doi: 10.2105/AJPH.2020.306045. Epub 2021 Jan 21.
The increased risk of harm from COVID-19 infection in pregnancy highlights the importance of including pregnant people in COVID-19 vaccine development and deployment. Promising vaccines being developed include replication-competent platforms, which are typically contraindicated during pregnancy because of theoretical risk. However, replicating vaccines are administered in and around pregnancy, either inadvertently because of unknown pregnancy status or when recommended.The historical cases of Ebola virus, yellow fever, and rubella demonstrate that contradictory messages around the safety of live vaccines in pregnancy have critical public health costs. First, restricting study or use of replicating vaccines in pregnancy may delay or deny access to the only available protection against deadly diseases. Additionally, not vaccinating pregnant people may slow epidemic control. Finally, uncertainty and worry around the safety of live vaccines may lead to terminations of otherwise desired pregnancies after inadvertent vaccination in pregnancy.If one of the vaccines deployed to combat the current global COVID-19 pandemic is replication competent, historical cases offer important lessons for ethical and effective protection for pregnant populations.
COVID-19 感染对孕妇造成的伤害风险增加,凸显了将孕妇纳入 COVID-19 疫苗研发和部署的重要性。正在开发的有前景的疫苗包括复制型平台,由于理论上的风险,这些平台在怀孕期间通常是禁忌的。然而,复制型疫苗在怀孕期间或临近怀孕期间被无意中接种,要么是因为未知的怀孕状况,要么是因为建议接种。埃博拉病毒、黄热病和风疹的历史案例表明,围绕活疫苗在怀孕期间安全性的矛盾信息对公共卫生造成了严重的代价。首先,限制在怀孕期间研究或使用复制型疫苗可能会延迟或剥夺针对致命疾病的唯一可用保护。此外,不接种孕妇可能会减缓疫情控制。最后,围绕活疫苗安全性的不确定性和担忧可能会导致在怀孕期间无意中接种疫苗后终止原本期望的妊娠。如果用于对抗当前全球 COVID-19 大流行的疫苗之一是复制型的,那么历史案例为保护孕妇提供了重要的经验教训,这对伦理和有效保护孕妇具有重要意义。